Skip to main content

Table 3 Events during the follow-up

From: Long-term outcome of percutaneous radiofrequency ablation for periportal hepatocellular carcinoma: tumor recurrence or progression, survival and clinical significance

Classification of all events Periportal HCC
(N = 56)
Nonperiportal HCC
(N = 177)
P value
Tumor Events after RFA
 LTP *15 (28.8%) 24 (13.6%) 0.0099
 IDR *23 (44.2%) 40 (22.6%) 0.0012
 Extrahepatic recurrence *12 (23.1%) 14 (7.9%) 0.0010
 PVTT 16 (28.6%) 12 (6.8%) <0.0001
2nd-line treatments
 TACE 1 3
 RFA 6 11
 TACE+RFA 11 18
 Surgical resection 3 4
 Liver transplantation 1 1
 Radiation therapy 1 0
 Systemic therapy 1 0
 Systemic therapy+TIPS 1 0
 Systemic therapy+TACE±RFA 5 9
 Support therapy 3 5
 Unknown 2 0
Major complication 0.1346
 Total 6 (10.7%) 9 (5.1%)
 Hepatic infraction 2 0
 Portal vein thrombosis 4 5
 Biloma 0 1  
 Liver abscess 0 1  
 Bleeding 0 2
  1. *Four patients in the periportal group were excluded to evaluate the LTP, IDR and extrahepatic metastasis due to technical failure of RFA